JACC
HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
 QUICK SEARCH:   [advanced]


     


J Am Coll Cardiol, 2000; 36:1612-1618
© 2000 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Mortara, A.
Right arrow Articles by Cobelli, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mortara, A.
Right arrow Articles by Cobelli, F.

CLINICAL STUDY

Nonselective beta-adrenergic blocking agent, carvedilol, improves arterial baroflex gain and heart rate variability in patients with stable chronic heart failure

Andrea Mortara, MDa, Maria Teresa La Rovere, MDa, Gian Domenico Pinna, BEa, Roberto Maestri, MD, BEa, Soccorso Capomolla, MDa and Franco Cobelli, MDa

a Department of Cardiology, Centro Medico di Montescano, "S. Maugeri" Foundation, IRCCS, Pavia, Italy

Manuscript received July 29, 1999; revised manuscript received April 10, 2000, accepted June 15, 2000.

Reprint requests and correspondence: Dr. Andrea Mortara, Division of Cardiology, Centro Medico di Montescano, "S. Maugeri" Foundation, IRCCS, Montescano, Pavia, Italy
amortara{at}fsm.it

OBJECTIVES

The purpose of this study was to investigate in a case-controlled study whether carvedilol increased baroreflex sensitivity and heart rate variability (HRV).

BACKGROUND

In chronic heart failure (CHF), beta-adrenergic blockade improves symptoms and ventricular function and may favorably affect prognosis. Although beta-blockade therapy is supposed to decrease myocardial adrenergic activity, data on restoration of autonomic balance to the heart and, particularly, on vagal reflexes are limited.

METHODS

Nineteen consecutive patients with moderate, stable CHF (age 54 ± 7 years, New York Heart Association [NYHA] class II to III, left ventricular ejection fraction [LVEF] 24 ± 6%), treated with optimized conventional medical therapy, received carvedilol treatment. Controls with CHF were selected from our database on the basis of the following matching criteria: age ± 3 years, same NYHA class, LVEF ± 3%, pulmonary wedge pressure ± 3 mm Hg, peak volume of oxygen ± 3 ml/kg/min, same therapy. All patients underwent analysis of baroreflex sensitivity (phenylephrine method) and of HRV (24-h Holter recording) at baseline and after six months.

RESULTS

Beta-blockade therapy was associated with a significant improvement in symptoms (NYHA class 2.1 ± 0.4 vs. 1.8 ± 0.5, p < 0.01), systolic and diastolic function (LVEF 23 ± 7 vs. 28 ± 9%, p < 0.01; pulmonary wedge pressure 17 ± 8 vs. 14 ± 7 mm Hg, p < 0.05) and mitral regurgitation area (7.0 ± 5.1 vs. 3.6 ± 3.0 cm2, p < 0.01). No significant differences were observed in either clinical or hemodynamic indexes in control patients. Phenylephrine method increased significantly after carvedilol (from 3.7 ± 3.4 to 7.1 ± 4.9 ms/mm Hg, p < 0.01) as well as RR interval (from 791 ± 113 to 894 ± 110 ms, p < 0.001), 24-h standard deviation of normal RR interval and root mean square of successive differences (from 56 ± 17 to 80 ± 28 ms and from 12 ± 7 to 18 ± 9 ms, all p < 0.05), while all parameters remained unmodified in controls. During a mean follow-up of 19 ± 8 months a reduced number of cardiac events (death plus heart transplantation, 58% vs. 31%) occurred in those patients receiving beta-blockade.

CONCLUSIONS

Besides the well-known effects on ventricular function, treatment with carvedilol in CHF restores both autonomic balance and the ability to increase reflex vagal activity. This protective mechanism may contribute to the beneficial effect of beta-blockade treatment on prognosis in CHF.

Abbreviations and Acronyms
  ANOVA = analysis of variance
  BRS = baroreflex sensitivity
  CHF = chronic heart failure
  HRV = heart rate variability
  LVEF = left ventricular ejection fraction
  NYHA = New York Heart Association
  rMSSD = root mean square of successive differences
  SAP = systolic arterial pressure
  SDNN = 24-h standard deviation of normal RR interval




This article has been cited by other articles:


Home page
J Am Coll CardiolHome page
C. Fantoni, S. Raffa, F. Regoli, F. Giraldi, M. T. La Rovere, J. Prentice, F. Pastori, S. Fratini, J. A. Salerno-Uriarte, H. U. Klein, et al.
Cardiac Resynchronization Therapy Improves Heart Rate Profile and Heart Rate Variability of Patients With Moderate to Severe Heart Failure
J. Am. Coll. Cardiol., November 15, 2005; 46(10): 1875 - 1882.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
G. D. Pinna, R. Maestri, S. Capomolla, O. Febo, E. Robbi, F. Cobelli, and M. T. La Rovere
Applicability and Clinical Relevance of the Transfer Function Method in the Assessment of Baroreflex Sensitivity in Heart Failure Patients
J. Am. Coll. Cardiol., October 4, 2005; 46(7): 1314 - 1321.
[Abstract] [Full Text] [PDF]


Home page
HeartHome page
K Y K Wong, S McSwiggan, N S J Kennedy, S Y S Wong, A Gavin, R S MacWalter, and A D Struthers
Spectrum of cardiac abnormalities associated with long QT in stroke survivors
Heart, October 1, 2005; 91(10): 1306 - 1310.
[Abstract] [Full Text] [PDF]


Home page
J Clin PharmacolHome page
B. F. McBride and C. M. White
Critical Differences Among Beta-Adrenoreceptor Antagonists in Myocardial Failure: Debating the MERIT of COMET
J. Clin. Pharmacol., January 1, 2005; 45(1): 6 - 24.
[Abstract] [Full Text] [PDF]


Home page
Am J Crit CareHome page
S. K. Hamlin, P. S. Villars, J. T. Kanusky, and A. D. Shaw
Role of Diastole in Left Ventricular Function, II: Diagnosis and Treatment
Am. J. Crit. Care., November 1, 2004; 13(6): 453 - 466.
[Abstract] [Full Text] [PDF]


Home page
JNMHome page
C. Kurata, A. Uehara, and A. Ishikawa
Improvement of Cardiac Sympathetic Innervation by Renal Transplantation
J. Nucl. Med., July 1, 2004; 45(7): 1114 - 1120.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
M. T. La Rovere, G. D. Pinna, R. Maestri, A. Mortara, S. Capomolla, O. Febo, R. Ferrari, M. Franchini, M. Gnemmi, C. Opasich, et al.
Short-Term Heart Rate Variability Strongly Predicts Sudden Cardiac Death in Chronic Heart Failure Patients
Circulation, February 4, 2003; 107(4): 565 - 570.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. J. Vittorio, C. C. Lang, S. D. Katz, M. Packer, D. M. Mancini, and U. P. Jorde
Vasopressor Response to Angiotensin II Infusion in Patients With Chronic Heart Failure Receiving {beta}-Blockers
Circulation, January 21, 2003; 107(2): 290 - 293.
[Abstract] [Full Text] [PDF]


Home page
CirculationHome page
T. H. Makikallio, H. V. Huikuri, M. T. La Rovere, G. D. Pinna, S. H. Hohnloser, F. I. Marcus, A. Mortara, R. Nohara, J. T. Bigger Jr, A. J. Camm, et al.
Risks in Risk Stratification: What Is Relevant in Practice? * Response
Circulation, March 26, 2002; 105 (12): e69 - e70.
[Full Text] [PDF]




HOME SUBSCRIPTIONS CURRENT ISSUE PAST ISSUES CARDIOSOURCE SEARCH HELP FEEDBACK
Copyright © 2000 by the American College of Cardiology Foundation.